[HTML][HTML] Poor birth outcomes in malaria in pregnancy: recent insights into mechanisms and prevention approaches

CLL Chua, W Hasang, SJ Rogerson, A Teo - Frontiers in immunology, 2021 - frontiersin.org
Pregnant women in malaria-endemic regions are susceptible to malaria in pregnancy, which
has adverse consequences on birth outcomes, including having small for gestational age …

[HTML][HTML] Progress and insights toward an effective placental malaria vaccine

B Gamain, A Chêne, NK Viebig… - Frontiers in …, 2021 - frontiersin.org
In areas where Plasmodium falciparum transmission is endemic, clinical immunity against
malaria is progressively acquired during childhood and adults are usually protected against …

PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study

SB Sirima, L Richert, A Chêne, AT Konate… - The Lancet Infectious …, 2020 - thelancet.com
Background PRIMVAC is a VAR2CSA-derived placental malaria vaccine candidate aiming
to prevent serious clinical outcomes of Plasmodium falciparum infection during pregnancy …

[HTML][HTML] Structural basis for placental malaria mediated by Plasmodium falciparum VAR2CSA

R Ma, T Lian, R Huang, JP Renn, JD Petersen… - Nature …, 2021 - nature.com
Plasmodium falciparum VAR2CSA binds to chondroitin sulfate A (CSA) on the surface of the
syncytiotrophoblast during placental malaria. This interaction facilitates placental …

[HTML][HTML] Structure-guided design of VAR2CSA-based immunogens and a cocktail strategy for a placental malaria vaccine

R Ma, ND Salinas, S Orr-Gonzalez… - PLoS …, 2024 - journals.plos.org
Placental accumulation of Plasmodium falciparum infected erythrocytes results in maternal
anemia, low birth weight, and pregnancy loss. The parasite protein VAR2CSA facilitates the …

[HTML][HTML] The delay in the licensing of protozoal vaccines: a comparative history

CB Palatnik-de-Sousa, D Nico - Frontiers in Immunology, 2020 - frontiersin.org
Although viruses and bacteria have been known as agents of diseases since 1546, 250
years went by until the first vaccines against these pathogens were developed (1796 and …

[HTML][HTML] Placental malaria vaccine candidate antigen VAR2CSA displays atypical domain architecture in some Plasmodium falciparum strains

JYA Doritchamou, R Morrison, JP Renn… - Communications …, 2019 - nature.com
Two vaccines based on Plasmodium falciparum protein VAR2CSA are currently in clinical
evaluation to prevent placental malaria (PM), but a deeper understanding of var2csa …

A single full-length VAR2CSA ectodomain variant purifies broadly neutralizing antibodies against placental malaria isolates

JYA Doritchamou, JP Renn, B Jenkins, A Mahamar… - Elife, 2022 - elifesciences.org
Placental malaria (PM) is a deadly syndrome most frequent and severe in first pregnancies.
PM results from accumulation of Plasmodium falciparum-infected erythrocytes (IE) that …

[HTML][HTML] Preclinical immunogenicity and safety of the cGMP-grade placental malaria vaccine PRIMVAC

A Chêne, S Gangnard, A Guadall, H Ginisty, O Leroy… - …, 2019 - thelancet.com
Background VAR2CSA is the lead antigen for developing a vaccine that would protect
pregnant women against placental malaria. A multi-system feasibility study has identified E …

[HTML][HTML] A conserved epitope in VAR2CSA is targeted by a cross-reactive antibody originating from Plasmodium vivax Duffy binding protein

U Iyamu, DF Vinals, B Tornyigah, E Arango… - Frontiers in Cellular …, 2023 - frontiersin.org
During Plasmodium falciparum infection in pregnancy, VAR2CSA is expressed on the
surface of infected erythrocytes (IEs) and mediates their sequestration in the placenta. As a …